Synthesis, solubility and antitumor activity of maslinic acid derivatives.

dc.centroFacultad de Cienciases_ES
dc.contributor.authorFuentes-Ríos, David
dc.contributor.authorCepero, Ana
dc.contributor.authorGarcía-Castro, Miguel
dc.contributor.authorContreras-Cáceres, Rafael
dc.contributor.authorLópez-Romero, Juan Manuel
dc.contributor.authorLuque, Cristina
dc.contributor.authorCabeza, Laura
dc.contributor.authorMelguizo, Consolación
dc.contributor.authorPrados, José
dc.date.accessioned2025-10-28T11:25:14Z
dc.date.available2025-10-28T11:25:14Z
dc.date.issued2022-02-05
dc.departamentoQuímica Orgánicaes_ES
dc.description.abstractMaslinic acid (MA), a pentacyclic triterpenoid obtained from olives that is characterized by its antiproliferative activity in tumor cells, has become a promising molecule that could be modi ed to improve cancer treatment. In this work we have synthesized in good yields several new MA conjugates, including glycerin, oligo(ethylene glycol), and amino acid derivatives (compounds 3a-f). The synthesis offers the possibility of recovering unreacted MA, and thus the scaling up of the process. For the tyramine-MA conjugate, compound 3f or TMA, the preparation has been optimized to a one-pot reaction. Solubility of conjugates in polar solvents has been measured, showing a marked increase of solubility with respect to MA. Moreover, we selected the tyramidyl maslinic acid conjugate (3f or TMA) to determine antitumor capacity over a wide range of cancer cell lines, including glioblastoma, mela- noma, breast, lung, colorectal and pancreatic cancer. Our results clearly demonstrated that TMA induced higher cytotoxicity in all cancer cell types compared to MA. TMA was more effective than MA, especially in breast cancer cells (MCF-7) and melanoma cells (B16–F10) where IC50 reductions of 4.12 and 4.72, respectively, was detected. Interestingly, TMA showed a remarkable antitumor ability against the resistant HCT-15 colon cancer cell line. Furthermore, we demonstrated for the rst time a relevant effect of a MA derivative against glioblastoma cells (A172 and SF-268). These results suggest that TMA is able to improve the antitumor characteristics of MA in a wide range of cancers and that it may be a promising compound for various tumor types, including resistant cancer.es_ES
dc.identifier.citationEuropean Journal of Medicinal Chemistry Reports 4 (2022) 100032es_ES
dc.identifier.doi10.1016/j.ejmcr.2022.100032
dc.identifier.urihttps://hdl.handle.net/10630/40476
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights.accessRightsopen accesses_ES
dc.subjectTriterpenoses_ES
dc.subjectEnlaces químicoses_ES
dc.subjectNeurotransmisoreses_ES
dc.subjectCánceres_ES
dc.subjectCitotoxicidad por mediación celulares_ES
dc.subject.otherPentacyclic triterpeneses_ES
dc.subject.otherChemical conjugateses_ES
dc.subject.otherTyraminees_ES
dc.subject.otherResistant canceres_ES
dc.subject.otherCytotoxicityes_ES
dc.titleSynthesis, solubility and antitumor activity of maslinic acid derivatives.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationdaaaa2dc-4012-4ad3-9fee-4a0da3e1181a
relation.isAuthorOfPublication.latestForDiscoverydaaaa2dc-4012-4ad3-9fee-4a0da3e1181a

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022 EJMCR 2022, 4, 100032 DEF.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
Description:

Collections